Morrison Foerster Client Alert, July 12, 2016

Biotech and pharmaceutical companies received critical guidance from the Federal Circuit yesterday, when the en banc court exempted a broad category of common manufacturing and supply arrangements from the reach of the patent law’s “on sale” bar.  In The Medicines Company v. Hospira, Inc., App. No.